Objective: To investigate the antitumor activities and apoptosis mechanisms of 3,7-dinitrodibenzobromonium salt (cBr) on human chronic myelogenous leukemia K562 cell line in vitro. Methods: The antitumor activities of cbr were tested by Trypanblau exclusion test, MTF coloretric assay and clonal forming test, and the mechanisms were studied by morphological analysis (microscopy, fluoreseencemicroscopy, electron microscopy) and flow cytometry analysis. Resuits: cBr could inhibit of the proliferation K562 cells and kill them significantly. The effects varied with different time and doses, and IC50 of cell colony forming rate was 0. 497 mmoL/L. Apoptosis rate tested by flow cytometry was 70.34%,and apoptotic characteristics could be found by microscopy and electron microscopy. Conclusion: cBr could inhibit K562 cell proliferation greatly, and could induce K562 cells into apoptosis.

OBJECTIVETo investigate the diagnosis and treatment of incidental prostate cancer (IPC) following transurethral plasma kinetic vaporization prostatectomy (TUPVP).

METHODSPathological examinations were conducted on 134 benign prostate hyperplasia specimens by means of series microtomy after TUPVP.

RESULTSFifteen cases of IPC were detected from the total number of TUPVP specimens, with a pick-up rate of 11.2%. Dual testicle resection with endocrine therapy was performed in 4 cases of Stage A2 patients, and endocrine therapy alone was conducted in 9 cases of Stage A1 patients. Thirteen patients were followed up for 7 to 15 months and all lived without cancer (PSA 0.15 - 4.0 microg/L).

CONCLUSIONTUPVP and series microtomy may be helpful to the diagnosis of IPC. Patients at Stage A1 need mere endocrine therapy, while those at Stage A2 warrant dual testicle resection.

Aged ; Aged, 80 and over ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Orchiectomy ; Prostate-Specific Antigen ; blood ; Prostatic Hyperplasia ; pathology ; surgery ; Prostatic Neoplasms ; pathology ; surgery ; Transurethral Resection of Prostate

Metabolic regulation has been proven to play a critical role in T cell antitumor immunity. However, cholesterol metabolism as a key component of this regulation remains largely unexplored. Herein, we found that the low-density lipoprotein receptor (LDLR), which has been previously identified as a transporter for cholesterol, plays a pivotal role in regulating CD8